Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.34 |
| ▸ | MEN1 | O00255 | 3/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.34 |
| ▸ | HPGD | P15428 | 1/20 | 0.34 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.34 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.34 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.34 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.34 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.34 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.34 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.34 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.34 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.34 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.34 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.34 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | ACACB | O00763 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6959426 | 0.87 | PSMB1 (0.33) | SMN1; SMN2ALDH1A1KDM4EMEN1KMT2A | |
| SCHEMBL6959150 | 0.86 | — | — | |
| SCHEMBL6959771 | 0.82 | KCNA3 (0.32) | KDM4E | |
| SCHEMBL14878212 | 0.81 | GAA (0.37) | SMN1; SMN2GAAALDH1A1KDM4EMEN1 | |
| SCHEMBL6960155 | 0.81 | — | — | |
| SCHEMBL6955686 | 0.81 | GNAI3 (0.34) | — | |
| SCHEMBL6961257 | 0.80 | PIK3CD (0.41) | ALDH1A1KDM4ETDP1 | |
| SCHEMBL19121148 | 0.80 | TDP1 (0.38) | SMN1; SMN2GAAALDH1A1KDM4EMEN1 | |
| SCHEMBL6958291 | 0.78 | KDM4E (0.35) | ALDH1A1KDM4EMEN1KMT2ATDP1 | |
| SCHEMBL6960555 | 0.76 | LTA4H (0.43) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9951051-B2 | Process for producing alkynylketone derivative | SHIONOGI & CO., LTD. (JP) | 2018-04-24 | — | — | US | disclosed |
| US-9951051-B2 | Process for producing alkynylketone derivative | SHIONOGI & CO., LTD. (JP) | 2018-04-24 | — | — | US | disclosed |
| US-20170197943-A1 | PROCESS FOR PRODUCING ALKYNYLKETONE DERIVATIVE | SHIONOGI & CO., LTD. (JP) | 2017-07-13 | — | — | US | disclosed |
| US-20170197943-A1 | PROCESS FOR PRODUCING ALKYNYLKETONE DERIVATIVE | SHIONOGI & CO., LTD. (JP) | 2017-07-13 | — | — | US | disclosed |
| US-8426589-B2 | Process for production of quinazoline derivative | SHIONOGI & CO., LTD. (JP) | 2013-04-23 | — | — | US | disclosed |
| US-8349857-B2 | Quinazoline derivatives having tyrosine kinase inhibitory activity | SHIONOGI & CO., LTD. (JP) | 2013-01-08 | — | — | US | disclosed |
| US-8202879-B2 | Quinazoline derivatives having tyrosine kinase inhibitory activity | SHIONOGI & CO., LTD. (JP) | 2012-06-19 | — | — | US | disclosed |
| US-20120123114-A1 | QUINAZOLINE DERIVATIVES HAVING TYROSINE KINASE INHIBITORY ACTIVITY | SHIONOGI & CO., LTD. (JP) | 2012-05-17 | — | — | US | disclosed |
| US-20110257391-A1 | PROCESS FOR PRODUCTION OF QUINAZOLINE DERIVATIVE | SHIONOGI & CO., LTD. (JP) | 2011-10-20 | — | — | US | disclosed |
| US-20090143414-A1 | Quinazoline Derivatives Having Tyrosine Kinase Inhibitory Activity | SHIONOGI & CO., LTD. (JP) | 2009-06-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110257391-A1 | PROCESS FOR PRODUCTION OF QUINAZOLINE DERIVATIVE | ABL1, MAP2K5, MAP2K2 | SMN1; SMN2 4442/4885GAA 1295/4885ALDH1A1 3485/4885 |
| US-20090143414-A1 | Quinazoline Derivatives Having Tyrosine Kinase Inhibitory Activity | ERBB2, EGFR, ABL1 | SMN1; SMN2 4182/4885GAA 1615/4885ALDH1A1 4593/4885 |
| US-20120123114-A1 | QUINAZOLINE DERIVATIVES HAVING TYROSINE KINASE INHIBITORY ACTIVITY | ERBB2, EGFR, ABL1 | SMN1; SMN2 4182/4885GAA 1615/4885ALDH1A1 4593/4885 |
| US-20170197943-A1 | PROCESS FOR PRODUCING ALKYNYLKETONE DERIVATIVE | PDK4, PDK3, PDK2 | SMN1; SMN2 3177/4885GAA 1571/4885ALDH1A1 560/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.